taxicat
05 Feb 2019
shock and awe!!! So…the board has been quiet on this share since Jul last year!!! Have IK missed something?
francieg3
12 Jul 2018
shock and awe!!! should read "about 3 weeks ago…
francieg3
12 Jul 2018
shock and awe!!! Emailed the BOD about weeks ago “Do you know of any material reason for the SP crash?†No response so far. The silence is deafening
osammyboy
09 Mar 2018
Re: shock and awe!!! Back to reality during the day but closes @ 147.5 up 50.5%. If only!
osammyboy
08 Mar 2018
shock and awe!!! Just opened my Barclays portfolio, Tils up 54.4% to 147.5. I wish. Back down to earth with a thump
osammyboy
06 Feb 2018
Re: trades Don't panic, Don't panicTotally misread that sale 10000 shares total £11200
osammyboy
06 Feb 2018
trades Total trades shown here as 11,646. LSE shows a single trade of 11,200,000 (OFF BOOK) @ 112p at 8.21 amOdd
osammyboy
08 Jun 2017
Top up Bad news this am but couldn't resist a 500 top up at 115.06.
Simbr
08 Jun 2016
Fundraise Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both milciclib and foralumab which brings the Group two research projects and two clinical programmes together plus research into a cancer stem cell diagnostic. Group’s successful fund raisings during the period demonstrated Board’s confidence as well as shareholders’ continuing support. Post the period, the Group raised a further £709,406 through the issue of unsecured convertible loan notes to existing shareholders, further expanded its highly experienced clinical development team and announced plans for additional development of foralumab in two clinical indications: i) graft vs host disease, and ii) ulcerative colitis. Moreover, the research agreement with Cardiff University has led to the identification of lead clinical candidate, CB1, a Bcl-3 inhibitor with potent anti-metastatic activity and impressive in-vivo efficacy and safety profile. An Investigational New Drug Application for CB1 will be filed in 2016, with clinical trials expected to begin before the year end. The strengthened balance sheet will support Tiziana to progress its existing and new clinical trials and give Group the resources to expand its presence internationally. We are encouraged by the Group’s performance last year and the commitment by existing investors."
Simbrad
08 Jun 2016
Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both milciclib and foralumab which brings the Group two research projects and two clinical programmes together plus research into a cancer stem cell diagnostic. Group’s successful fund raisings during the period demonstrated Board’s confidence as well as shareholders’ continuing support. Post the period, the Group raised a further £709,406 through the issue of unsecured convertible loan notes to existing shareholders, further expanded its highly experienced clinical development team and announced plans for additional development of foralumab in two clinical indications: i) graft vs host disease, and ii) ulcerative colitis. Moreover, the research agreement with Cardiff University has led to the identification of lead clinical candidate, CB1, a Bcl-3 inhibitor with potent anti-metastatic activity and impressive in-vivo efficacy and safety profile. An Investigational New Drug Application for CB1 will be filed in 2016, with clinical trials expected to begin before the year end. The strengthened balance sheet will support Tiziana to progress its existing and new clinical trials and give Group the resources to expand its presence internationally. We are encouraged by the Group’s performance last year and the commitment by existing investors."
osammyboy
28 Apr 2016
no buying With sp @110 and bid @ 115 I tried buying 2500 online at Barclays. Quoted 187.4 Obviously buying is being discouraged for whatever reason
osammyboy
15 Jan 2016
More cheap shares for the boys. When can we get some?
Nige the snake
10 Jan 2016
three of the best Hi I thought i would try an experiment and ask members of this bb to suggest 3 good share tips for 2016. The idea is to post this same message on other bbs where the sp has done well over the last year and give feedback after listing them all on a virtual portfolio. Its not a competition its to get and share information. If I get enough takers I will set up a Facebook Group with all the information received.My three are 1 African Potash,2 Vodaphone,and 3 Hydrodec.
goondaft
06 Dec 2015
brilliant have not looked at this one since old days of alexander , d ,nice surprise well more than doubled my money
Richens
11 Aug 2015
Re: Signifcant price rises?? Firstly, the valuation of BioTech companies like these are always based around a lot of speculation.What is the speculation with Tiziana you wonder?Well back at the start of May they licensed a new compound called 'OH14' which is able to fight cancer on many fronts!They are initially concentrating mainly on Breast Cancer and hope that human trials will prove the drug in that not too distant future.I think the price rise comes from a few simple ponders- How much is a compound worth capable of stopping cancer- Mention of how 1% of any takeover bid goes to the University in Cardiff who developed the compound who Tiziana fund(drug companies get bought out for billions)There has been noticeable consistent big buys of around the £12k and £8k area recently & today.These buys show someone is fairly confident still at these levels. Personally I wouldn't be surprised if there is a takeover bid for anywhere between 500m and 2000m.And that kind of calibre would be needed to get this compound into a drug able to produce in mass for THE WORLD.Current MCap = 220m[link]
